These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 20663032)

  • 1. PEGylation of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) results in decreased uptake into rats and human liver.
    Saito-Yabe M; Kasuya Y; Yoshigae Y; Yamamura N; Suzuki Y; Fukuda N; Honma M; Yano K; Mochizuki S; Okada F; Okada A; Nagayama Y; Tsuda E; Fischer T; Höpner U; Zaja S; Mueller J; Okada J; Kurihara A; Ikeda T; Okazaki O
    J Pharm Pharmacol; 2010 Aug; 62(8):985-94. PubMed ID: 20663032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel comb-shaped PEG modification enhances the osteoclastic inhibitory effect and bone delivery of osteoprotegerin after intravenous administration in ovariectomized rats.
    Miyaji Y; Kasuya Y; Furuta Y; Kurihara A; Takahashi M; Ogawara K; Izumi T; Okazaki O; Higaki K
    Pharm Res; 2012 Nov; 29(11):3143-55. PubMed ID: 22729371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.
    Yano K; Tsuda E; Washida N; Kobayashi F; Goto M; Harada A; Ikeda K; Higashio K; Yamada Y
    J Bone Miner Res; 1999 Apr; 14(4):518-27. PubMed ID: 10234572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy.
    Yano K; Shibata O; Mizuno A; Kobayashi F; Higashio K; Morinaga T; Tsuda E
    Biochem Biophys Res Commun; 2001 Oct; 288(1):217-24. PubMed ID: 11594776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and disposition of recombinant human osteoprotegerin (rhOPG) after intravenous administration in female fischer rats.
    Miyaji Y; Kurihara A; Kamiyama E; Shiiki T; Kawai K; Okazaki O
    Xenobiotica; 2009 Feb; 39(2):113-24. PubMed ID: 19255937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Osteoclastogenesis inhibitory factor (OCIF)/OPG].
    Tsuda E; Higashio K
    Nihon Rinsho; 1998 Jun; 56(6):1435-9. PubMed ID: 9648461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis.
    Doschak MR; Kucharski CM; Wright JE; Zernicke RF; Uludağ H
    Mol Pharm; 2009; 6(2):634-40. PubMed ID: 19718808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells.
    Murakami T; Yamamoto M; Ono K; Nishikawa M; Nagata N; Motoyoshi K; Akatsu T
    Biochem Biophys Res Commun; 1998 Nov; 252(3):747-52. PubMed ID: 9837778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human dental mesenchymal cells and epithelial cells.
    Sakata M; Shiba H; Komatsuzawa H; Fujita T; Ohta K; Sugai M; Suginaka H; Kurihara H
    J Bone Miner Res; 1999 Sep; 14(9):1486-92. PubMed ID: 10469276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
    Mochizuki S; Kiyokawa A; Nagayama Y
    Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice.
    Tyagi AM; Gautam AK; Kumar A; Srivastava K; Bhargavan B; Trivedi R; Saravanan S; Yadav DK; Singh N; Pollet C; Brazier M; Mentaverri R; Maurya R; Chattopadhyay N; Goel A; Singh D
    Mol Cell Endocrinol; 2010 Aug; 325(1-2):101-9. PubMed ID: 20570709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat.
    Yamamoto M; Murakami T; Nishikawa M; Tsuda E; Mochizuki S; Higashio K; Akatsu T; Motoyoshi K; Nagata N
    Endocrinology; 1998 Sep; 139(9):4012-5. PubMed ID: 9724059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG)].
    Okada F; Tsuda E
    Clin Calcium; 2002 Aug; 12(8):1157-64. PubMed ID: 15775414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
    Takayanagi H; Iizuka H; Juji T; Nakagawa T; Yamamoto A; Miyazaki T; Koshihara Y; Oda H; Nakamura K; Tanaka S
    Arthritis Rheum; 2000 Feb; 43(2):259-69. PubMed ID: 10693864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells.
    Nakagawa N; Yasuda H; Yano K; Mochizuki Si; Kobayashi N; Fujimoto H; Shima N; Morinaga T; Chikazu D; Kawaguchi H; Higashio K
    Biochem Biophys Res Commun; 1999 Nov; 265(1):158-63. PubMed ID: 10548507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure.
    Kazama JJ; Shigematsu T; Yano K; Tsuda E; Miura M; Iwasaki Y; Kawaguchi Y; Gejyo F; Kurokawa K; Fukagawa M
    Am J Kidney Dis; 2002 Mar; 39(3):525-32. PubMed ID: 11877571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of secretion of osteoprotegerin in rat dental follicle cells.
    Wise GE; Ding D; Yao S
    Eur J Oral Sci; 2004 Oct; 112(5):439-44. PubMed ID: 15458504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble glucocorticoid-induced tumor necrosis factor receptor stimulates osteoclastogenesis by down-regulation of osteoprotegerin in bone marrow stromal cells.
    Shin HH; Kim SJ; Kang SY; Lee DS; Choi HS
    Bone; 2006 Oct; 39(4):716-23. PubMed ID: 16750437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coculture of osteoclast precursors with rheumatoid synovial fibroblasts induces osteoclastogenesis via transforming growth factor beta-mediated down-regulation of osteoprotegerin.
    Hase H; Kanno Y; Kojima H; Sakurai D; Kobata T
    Arthritis Rheum; 2008 Nov; 58(11):3356-65. PubMed ID: 18975335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.